Claims
- 1. A compound selected from 1-R-4-(omega-substituted alkyl)-3,3-diphenyl-2-pyrrolidinones of the formula: ##STR9## wherein; R is selected from the group consisting of hydrogen, lower-alkyl, cyclohexyl and benzyl,
- R.sup.1 is selected from the group consisting of hydrogen, chloro, bromo, fluoro, trifluoromethyl and lower-alkoxy,
- R.sup.2 is selected from the group consisting of hydrogen, chloro, bromo and fluoro,
- A is selected from the group consisting of lower-alkylcarbonyloxy and lower-alkoxycarbonyl, and n is 1, 2 or 3.
- 2. A pharmaceutically acceptable acid addition salt of a compound of claim 1.
- 3. A compound of claim 1 wherein n is 1.
- 4. A compound of claim 1 wherein n is 2.
- 5. A compound of claim 1 wherein n is 3.
- 6. A compound of claim 1 wherein n is 2 and A is lower-alkylcarbonyloxy.
- 7. A compound of claim 1 wherein n is 2 and A is lower-alkoxycarbonyl.
- 8. A compound of claim 1 wherein n is 3 and A is lower-alkylcarbonyloxy.
- 9. A compound of claim 1 wherein n is 3 and A is lower-alkoxycarbonyl.
- 10. 1-Isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-propionoxypiperidinyl)ethyl]-2-pyrrolidinone.
- 11. A pharmaceutically acceptable acid addition salt of the compound of claim 10.
- 12. 1-Isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-ethoxycarbonylpiperidinyl)ethyl]-2-pyrrolidinone.
- 13. A pharmaceutically acceptable acid addition salt of the compound of claim 12.
- 14. 1-Isopropyl-3,3-diphenyl-4-[2-(4-hydroxy-4-phenylpiperidinyl)ethyl]-2-pyrrolidinone.
- 15. 3,3-Diphenyl-1-isopropyl-4-(4-phenyl-4-hydroxypiperidinylmethyl)-2-pyrrolidinone.
- 16. A compound selected from the group consisting of compounds having the formula: ##STR10## wherein; R is selected from the group consisting of hydrogen, lower-alkyl, cyclohexyl and benzyl,
- R.sup.1 is selected from the group consisting of hydrogen, chloro, bromo, fluoro, trifluoromethyl and lower-alkoxy,
- R.sup.2 is selected from the group consisting of hydrogen, chloro, bromo and fluoro, and n is 1, 2 or 3.
- 17. A pharmaceutically acceptable acid addition salt of a compound of claim 16.
- 18. A compound of claim 16 wherein n is 1.
- 19. A compound of claim 16 wherein n is 2.
- 20. A compound of claim 16 wherein n is 3.
- 21. A method for the treatment of a warm blooded animal afflicted with pain which comprises administering to said animal in an amount sufficient to relieve said pain, a compound selected from the group consisting of 1-R-4-(omega-substituted alkyl)-3,3-diphenyl-2-pyrrolidinones of the formula: ##STR11## wherein; R is selected from the group consisting of hydrogen, lower alkyl, cyclohexyl and benzyl,
- R.sup.1 is selected from the group consisting of hydrogen, chloro, bromo, fluoro, trifluoromethyl and lower-alkoxy,
- R.sup.2 is selected from the group consisting of hydrogen, chloro, bromo and fluoro,
- A is selected from the group consisting of lower-alkylcarbonyloxy and lower-alkoxycarbonyl, and n is 2 or 3.
- 22. Method according to claim 21 wherein the pharmaceutically acceptable acid addition salts of the compounds are used.
- 23. Method according to claim 21 wherein n is 2.
- 24. Method according to claim 21 wherein n is 3.
- 25. Method according to claim 21 wherein n is 2 and A is lower-alkylcarbonyloxy.
- 26. Method according to claim 21 wherein n is 2 and A is lower-alkoxycarbonyl.
- 27. Method according to claim 21 wherein n is 3 and A is lower-alkylcarbonyloxy.
- 28. Method according to claim 21 wherein n is 3 and A is lower-alkoxycarbonyl.
- 29. Method according to claim 23 which comprises administering to said animal from 1 to 500 mg. of said compound.
- 30. Method according to claim 21 wherein said compound is 1-isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-propionoxypiperidinyl)ethyl]-2-pyrrolidinone.
- 31. Method according to claim 21 wherein said compound is 1-isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-ethoxycarbonylpiperidinyl)ethyl]-2-pyrrolidinone.
- 32. An analgetic composition comprising (a) 1 to 500 mg. of a compound selected from the group consisting of 1-R-4-(omega-substituted alkyl)-3,3-diphenyl-2-pyrrolidinones of the formula: ##STR12## wherein; R is selected from the group consisting of hydrogen, lower-alkyl, cyclohexyl,
- R.sup.1 is selected from the group consisting of hydrogen, chloro, bromo, fluoro, trifluoromethyl and lower-alkoxy,
- R.sup.2 is selected from the group consisting of hydrogen, chloro, bromo and fluoro,
- A is selected from the group consisting of lower-alkylcarbonyloxy and lower-alkoxycarbonyl, and n is 2 or 3, and
- (b) a pharmaceutically acceptable acid addition salt thereof in admisture with a pharmaceutically acceptable carrier.
- 33. The composition of claim 32 wherein the compound is 1-isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-propionoxypiperidinyl)ethyl]-2-pyrrolidinone.
- 34. The composition of claim 32 wherein the compound is 1-isopropyl-3,3-diphenyl-4-[2-(4-phenyl-4-ethoxycarbonylpiperidinyl)ethyl]-2-pyrrolidinone.
Parent Case Info
This application is a continuation-in-part of copending application Ser. No. 615,952 filed Sept. 23, 1975 now abandoned, which is a continuation-in-part of copending application Ser. No. 541,684 filed Jan. 16, 1975, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3192230 |
Lunsford et al. |
Jun 1965 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
615952 |
Sep 1975 |
|
Parent |
541684 |
Jan 1975 |
|